Rocket Pharmaceuticals In... (RCKT)
Rocket Pharmaceuticals Statistics
Share Statistics
Rocket Pharmaceuticals has 106.63M shares outstanding. The number of shares has increased by 17.46% in one year.
Shares Outstanding | 106.63M |
Shares Change (YoY) | 17.46% |
Shares Change (QoQ) | 0.28% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 98.97M |
Failed to Deliver (FTD) Shares | 27.26K |
FTD / Avg. Volume | 1.63% |
Short Selling Information
The latest short interest is 11.7M, so 11% of the outstanding shares have been sold short.
Short Interest | 11.7M |
Short % of Shares Out | 11% |
Short % of Float | 11.91% |
Short Ratio (days to cover) | 6.8 |
Valuation Ratios
The PE ratio is -4.61 and the forward PE ratio is -4.51. Rocket Pharmaceuticals's PEG ratio is 0.71.
PE Ratio | -4.61 |
Forward PE | -4.51 |
PS Ratio | 0 |
Forward PS | 0.9 |
PB Ratio | 2.57 |
P/FCF Ratio | -5.68 |
PEG Ratio | 0.71 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rocket Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.3, with a Debt / Equity ratio of 0.06.
Current Ratio | 9.3 |
Quick Ratio | 9.3 |
Debt / Equity | 0.06 |
Debt / EBITDA | -0.09 |
Debt / FCF | -0.12 |
Interest Coverage | 144.86 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-865.37K |
Employee Count | 299 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -75.3% in the last 52 weeks. The beta is 1.02, so Rocket Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.02 |
52-Week Price Change | -75.3% |
50-Day Moving Average | 9.38 |
200-Day Moving Average | 15.49 |
Relative Strength Index (RSI) | 29.99 |
Average Volume (20 Days) | 1.67M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -273.2M |
Net Income | -258.75M |
EBITDA | -273.2M |
EBIT | -260.63M |
Earnings Per Share (EPS) | -2.73 |
Balance Sheet
The company has 163.63M in cash and 25.5M in debt, giving a net cash position of 138.14M.
Cash & Cash Equivalents | 163.63M |
Total Debt | 25.5M |
Net Cash | 138.14M |
Retained Earnings | -1.22B |
Total Assets | 527.7M |
Working Capital | 337.5M |
Cash Flow
In the last 12 months, operating cash flow was -209.72M and capital expenditures 0, giving a free cash flow of -209.72M.
Operating Cash Flow | -209.72M |
Capital Expenditures | 0 |
Free Cash Flow | -209.72M |
FCF Per Share | -2.21 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for RCKT is $47, which is 648.4% higher than the current price. The consensus rating is "Buy".
Price Target | $47 |
Price Target Difference | 648.4% |
Analyst Consensus | Buy |
Analyst Count | 10 |
Stock Splits
The last stock split was on Jan 5, 2018. It was a backward split with a ratio of 1:4.
Last Split Date | Jan 5, 2018 |
Split Type | backward |
Split Ratio | 1:4 |
Scores
Altman Z-Score | 2.55 |
Piotroski F-Score | 3 |